Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Thalassaemia

- PMLiVE

To name and shame substandard healthcare?

Improving care by ‘naming and shaming’ hospitals or doctors remains a thorny issue

- PMLiVE

Driving good practice in homecare

The release of new professional standards looks to underpin the quality, and continued rise, of homecare services in the UK

- PMLiVE

Novartis’ Lucentis wins fourth NICE recommendation

But eye drug only recommended after a price-cutting patient access scheme offered

- PMLiVE

Former Blair adviser to lead NHS England

Simon Stevens to succeed David Nicholson

- PMLiVE

Walgreens: UK homecare sector could learn from the US

Pharmacy chain calls on UK to focus more on measuring the benefits of homecare

- PMLiVE

Pharmacy sales partners

How do you choose the right contract sales and marketing partner for your needs?

- PMLiVE

Homecare must be part of UK health debate, says NCHA

New CEO promises “greater leadership and clearer advocacy”

- PMLiVE

UK’s Cancer Drugs Fund given new lease of life

Government invests £400m and pledges Fund will remain until 2016

- PMLiVE

Delivering ‘beyond the pill’

Communicating added value is now crucial for market access programmes

- PMLiVE

Steve Field to lead inspection of primary care in England

Joins CQC as chief inspector of general practice

Novartis building

NICE backs Novartis’ Jetrea in rare eye condition

Recommends drug be available for NHS use to treat vitreomacular traction

National Institute for Health and Care Excellence NICE logo

NICE turns down Afinitor for breast cancer

NHS patients in England and Wales will not have routine access to Novartis’ drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links